![](/wp-content/uploads/2020/12/Ionis-Event.png)
$599
Ionis Hosts 2022 Investor Day; Intercept Withdraws OCA MAA in NASH
A series of cardiometabolic-related news items have been observed: Ionis hosted its 2022 Investor Day (view slides), and Intercept announced it has withdrawn the obeticholic acid (OCA) Marketing Authorization Application for the treatment of fibrosis due to NASH. Below, FENIX provides highlights and insights from the respective news items.